Рекомбинантный человеческий эритропоэтин в лечении анемии у детей со злокачественными опухолевыми заболеваниями
Диссертация
Роль дефектной продукции эритропоэтина (ЭПО), как одной из главных причин анемии, сопровождающей онкологические заболевания, доказанная многими исследованиями у взрослых пациентов, до сих пор дискутируется по отношению к детям со злокачественными опухолями. Результаты различных исследований по изучению адекватности выработки ЭПО у детей со злокачественными новообразованиями в ответ на анемию… Читать ещё >
Список литературы
- Владимирская Е.Б. Биологические основы противоопухолевой терапии. М., 2001
- Волчек И.В. Использование рекомбинантного эритропоэтина человека в онкогематологии. Terra Medica, 2002- 2: с. 17−19
- Камушкина О.Н., Демихов В. Г., Морщакова Е. Ф. Продукция сывороточного эритропоэтина при некоторых видах анемии у детей. Вопросы современной педиатрии, 2003: с. 144
- Марш В.А., Раскати K.JI. Мета-анализ эффективности эритропоэтина у больных с почечной патологией и онкологическими заболеваниями в терминальной стадии. Ж. Анемия у онколгических больных, 2002- 1(1): с.16—17
- Павлов А.Д. Эритропоэтин: достижения и перспективы. Гематология и трансфузиология, 1997- 42(1): с.25−29
- Павлов А.Д., Морщакова Е. Ф. Метаболизм железа и его регуляция. В сборнике: Дефицит железа и железодефицитная анемия у детей. М., 2001: с.7−24
- Павлов А.Д., Морщакова Е. Ф., Румянцев А. Г. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантным человеческим эритропоэтином. Современная онкология, 2002- 4: с.50−54
- Румянцев А. Г, Токарева Ю. Н. Анемия у детей: диагностика и лечение. Практическое пособие для врачей. М., 2000: с. 17−21
- Румянцев А.Г., Аграренко В. А. Гемотрансфузионная терапия в педиатрии и неонатологии. М., 2002
- Румянцев А.Г., Морщакова Е. Ф., Павлов А. Д. Эритропоэтин в диагностике, профилактике и лечении анемий. М., 2003
- Скобин В. Б, Камушкина О. Н., Морщакова Е. Ф. Оценка уровня сывороточного эритропоэтина (ЭПО). Проблемы гематологии и переливания крови, 2002- 1: с.78−79
- Скобин В.Б., Павлов А. Д., Морщакова Е. Ф., Ежманн В. ФНО-бета ингибирует ЭПО продукцию в HepG2 клетках. Гематология и трансфузиология, 1998- 43: с.28−30
- Abels R.I. Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol 1992- 87 (Suppl.l): p.4−11
- Beck M.N., Beck D. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med. Pediatr. Oncol. 1995- 25(1): p. 17−21
- Begnin Y. Erythropoiesis and erythropoietin in multiple myeloma. Leuk. Lymphoma 1995- 18: p.413−21
- Beguin Y., Baron F., Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica 1998- 83(12): p. 1076−81
- Beguin Y., demons G.K., Pootrakul P. et al. Quantitative assesment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993- 81: p. 1067−76
- Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin. Belg. 1996- 51: p.36−52
- Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin. Oncol. 1998- 25 (Suppl.7): p.27−34
- Bennetts G., Bertolone S., Bray G. et al. Erythropoietin reduces volume of red cell transfusions required in some subsets of children with acute lymphocytic leukaemia. Blood 1995- 86 (Suppl.l): p.853a
- Bolonaki J., Stiakaki E., Lydaki E. et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr. Hematol. Oncol. 1996- 13: p.111−121
- Buyukpamukcu M., Varan A., Kutluk T. et al. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med. Pediatr. Oncol. 2002- 39(4): p.455−8
- Cascinu S., Fedeli A., Del Ferro E. et al. Recombinant human erythropoietin treatment n cisplatin-assocated anemia: a randomized, double-blind trial with placebo. Clin. Oncol. 1994- 12(5): p.1058−62
- Case D.C.Jr., Bukowski R.M., Carey R.W. et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. Natl. Cancer Inst. 1993- 85(10): p.801−6
- Cazzola M., Mercuriali F., Brugnara C. Use of recombinant human erythropoietin outside the setting. Blood 1997- 89: p.4248−67
- Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995- p.4446−53
- Cazzola M., Ponchio L., Beguin Y. et al. Subcutaneous erythropoietin for treatment a refractory anemia in hematologic disorders. Results of a phase -I/II clinical trial. Blood 1992- 79: p.29−37
- Cazzola M., Ponchio L., Pedrotti C. et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemic of malignancy. Haematologica 1996- 81: p.434−41
- Corazza F., Andre M., Bergmann P. et al. Assessment of the physiopathology of anemia in children with cancer by simultaneous serum erythropoietin and transferrin receptor measurements. Blood 1995- 86 (Suppl.l): p.480a
- Corazza F., Beguin Y., Bergmann P. et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood 1998- 92(5): p. 1793−8
- Csaki C., Ferencz T., Schuler D. et al. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur. J. Cancer. 1998- 34(3): p.364−7
- Danielson B. R-huepo hyporesponsiveness Who and why?- Nephrol. Dial. Transplant. 1995- 10: p.69−73
- Del Mastro L., Venturini M., Lionetto R. et al. Randomized phase III trial evaluating the role of erythropoietin in prevention of chemotherapy-induced anemia. Clin. Oncol. 1997- 15(7): p.2715−21
- Demetri G.D. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br. J. Cancer. 2001- 84 (Suppl.l): p.31−37
- Dornbusch P. Clinical efficacy of r-HuEPO in the treatment of cancer-related anemia in pediatric patients. Erythropoiesis 1996- 7: p.40−45
- Dowd M.D., Morgan E.R., Langman C.B., Murphy S. Serum erythropoietin levels in children with leukemia. Med. Pediatr. Oncol. 1997- 28(4): p.259−67
- Dubray B., Mosser V., Brunin F. et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospectiva study. Radiology 1996- 201: p.553−58
- Estrin J.T., Schoret L., Kregenow R., Henry D.H. A retrospective review of blood transfusions in cancer patients with anemia. The Oncologist. 1999- 4: p.318−324
- Fein D.A., Lee W.R., Hanlon A.L. et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. Clin. Oncol. 1995- 13: p.2077−83
- Ferencz T., Csaki C., Apjok E. et al. Transfusion requirements after chemotherapy in paediatric solid tumour patients. Erythropoiesis 1994- 5: p.115−18
- Fillet G., Beguin Y., Baldelli L. Model of reticuloendothelial iron metabolism in humans: Abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1998- 74: p.844−51
- Gamucci T., Thorel M.F., Frasca A.M. et al. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur. J. Cancer. 1993- 29A (Suppl.2): p.13−4
- Glaspy J., Cavill J. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 1995- 13: p.461−73
- Glimelius B., Linne T., Hoffman K. et ai. Epoetin beta in the treatment of anemia in patients with advanced gastroiritesinal cancer. Clin. Oncol. 1998- 16(2): p.434−40
- Grogan M., Thomas G.M., Melamed J. et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999- 86: p.1528−36
- Hellebostad M., Marstrander J., Slordahl S.H. et al. Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease-andthe effects of treatment. Haematol. 1990- 44(3): p. 159−64
- Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodusplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 1995- 89: p.65−71
- Henry D., Abels R., Larholt K. Prediction of response to recombinant human erythropoietin (r-huepo / epoetin alpha) therapy in cancer patients. Blood 1995- 85: p.1676−78
- Hockel M., Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001- 28 (2 Suppl.8): p.36−41
- Hockenberry M.J., Hinds P. S., Barrera P. et al. Incidence of anemia in children with solid tumors or Hodgkin disease. Pediatr. Hematol. Oncol. 2002- 24(1): p.35−7
- Howrousian M.R., Kasper C., Oberhoff C. et al. Pathophysiology of cancer-related anemia. In: rh Erythropoietin in cancer supportive treatment. Marcel Dekker Inc., N.Y. 1996- p. 13−34
- Jelkmann W., Wolff M., Fandrey J. Inhibition of erythropoietin production by cytokines and chemotherapy may contribute to the anemia in malignant diseases. Oxigen Transport to Tissue / Ed by P. Waupel et al., Plenum Press., N.Y. 1994- p.525−30
- Kalmanti M., Kalmantis T. Committed erythroid progenitors and anemic children with limphomas and tumors. Pediatr. Hematol. Oncol. 1989- 6: p.85−93
- Kaltwasser J.P., Gottschalk R. Erythropoietin and iron. Kidney Int., 1999- 55 (Suppl.69): p.49−56
- Kettelhack C., Schoter D., Matthias D., Schlag P.M. Serum erythropoietin levels in patients with solid tumors. Eur. J. Cancer 1994- 30A: p. 1289−91
- Kim M., Lee J., Wu C. et al. Defective erythropoiesis in bone marrow is a mechanism of anemia in children with cancer. Korean. Med. Sci. 2002- 17(3): p.337−40
- Kronberger M., Fischmeister G., Poetschger U. et al. Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr. Hematol. Oncol. 2002- 19(2): p.95−105
- Kronberger M., Keck B., Zoubek A. et al. Prevention of anemia with r-Hu-EPO in children with Ewing’s or osteogenic sarcoma. In: Perry MC, editor. Proceedings of the 31 st Annual Meeting of the American Society of
- Clinical Oncology- 1995 May 20−23- Los Angeles. Toronto: WB Saundeis 1995: p.258
- Leon P., Jimenez M., Barona P. et al. Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response. An Esp. Pediatr. 1998- 49(1): p. 17−22
- Leon P., Jimenez M., Barona P. et al. Recombinant erythropoietin in the treatment of chemotherapy-induced anemia in pediatric patients. Pediatr. Res. 1995- 38: p.441
- Leon P., Jimenez M., Barona P. et al. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med. Pediatr. Oncol. 1998−30(2): p. 110−6
- Ludwig H., Fritz E., Laitgeb C. et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994- 84: p. 1056−63
- Ludwig H., Fritz E. Anemia in cancer patients. Semin. Oncol. 1998- 25: p.2−6
- Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med. Pediatr. Oncol. 2002- 39(4): p.448−50
- Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl. J. Med. 1990- 322 (24): p. 1689−92
- Mott M.G., Bargess M.F. Paediatric malignancy. Medicine 1995- 23: p.460−63
- Osterborg A., Boogaerts M.A., Cimino R. et al. Recombinant human erythropoietin in transfusion-dependent anemia patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multicenter study. Blood 1996- 87: p.2675−82
- Ponchio L., Beguin Y., Farina G. et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 1992- 77: p.494−501
- Ponka P., Beaumont C., Richardson D.R. Function and regulation of transferrin and ferritin. Semin. Hematol. 1998- 35: p.35−54
- Richardson D.R., Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta. 1997- 1331: p. 1−40
- Rizzo J.D., Lichtin A.E., Woolf S.H. et al. Use of epoetin in patients with cancer: evidence bused clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002- 100: p.2303−20
- Rose E.H., Abels R.J., Nelson R.A. et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia. Br. J. Haematol. 1995- 89: p.831−37
- Roy C.N., Weinstein D.A., Andrews N.C. Mead Johnson Award for Research in Pediatrics Lecture: the molecular biology of the anemia of chronic disease: a hypothesis. Pediatr. Res. 2003- 53(3): p.507−12
- Ruggiero A., Riccardi R. Interventions for anemia in pediatric cancer patients. Med. Pediatr. Oncol. 2002-.39(4): p.451−4
- Schapira L., Antin J.H., Ransil B. et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990- 76: p.2354−59
- Smith D.H., Guarnieri C.M., Whaling S.M., Vokes E.E. Erythropoietin response in cancer patients receving cisplatin. Proc. Am. Assoc. Cancer Res. 1988- 29: p.52−56
- Stenke L., Wallvik J., Celsing F. et al. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993- 7: p. 1324−27
- Stockman J.A. Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatr. Clin. North. Am. 1986- 33: p. 111−28
- Varan A., Buyukpamukcu M., Kutluk T. et al. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics. 1999- 103 (2): p. E16
- Vaupel P., Kelleher D.K., Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001 -28 (2 Suppl.8): p.29−35
- Weinberg E.D. The role of iron in cancer. Eur. J. Cancer Prev. 1996- 5: p. 19−36
- Wolff M., Jelkmann W. Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann. Hematol. 1993- 66: p.27−31
- Zoubek A., Kronberger M. Early epoetin alfa treatment in children with solid tumors. Med. Pediatr. Oncol. 2002- 39(4): p.459−62